{"id":69038,"date":"2026-06-29T21:23:36","date_gmt":"2026-06-29T13:23:36","guid":{"rendered":"https:\/\/flcube.com\/?p=69038"},"modified":"2026-06-29T21:23:37","modified_gmt":"2026-06-29T13:23:37","slug":"eli-lillys-jaypirca-wins-chmp-recommendation-for-all-line-cll-treatment-regardless-of-prior-btk-inhibitor-use","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=69038","title":{"rendered":"Eli Lilly&#8217;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Eli Lilly and Company (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE: LLY<\/a>)<\/strong> announced on June 26, 2026, that the <strong>European Medicines Agency&#8217;s (EMA) Committee for Medicinal Products for Human Use (CHMP)<\/strong> has issued a <strong>positive opinion<\/strong> recommending approval of <strong>Jaypirca (pirtobrutinib)<\/strong> for the treatment of <strong>adult patients with chronic lymphocytic leukemia (CLL)<\/strong> across <strong>all lines of therapy<\/strong> and <strong>regardless of prior BTK inhibitor treatment history<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-regulatory-approval-timeline\" class=\"wp-block-heading\">Regulatory Approval Timeline<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Date<\/th><th>Jurisdiction<\/th><th>Indication<\/th><th>Key Differentiator<\/th><\/tr><\/thead><tbody><tr><td><strong>Oct 2024<\/strong><\/td><td>China<\/td><td>Relapsed\/refractory MCL (\u22652 prior therapies, including BTKi)<\/td><td>First approval globally<\/td><\/tr><tr><td><strong>Feb 2026<\/strong><\/td><td>China<\/td><td>Second-line CLL\/SLL<\/td><td>Earlier treatment line expansion<\/td><\/tr><tr><td><strong>Jun 2026<\/strong><\/td><td>EU (CHMP)<\/td><td>All-line CLL regardless of BTKi prior use<\/td><td><strong>Unprecedented treatment flexibility<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-mechanism-of-action\" class=\"wp-block-heading\">Drug Profile &amp; Mechanism of Action<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> Pirtobrutinib (Jaypirca)<\/li>\n\n\n\n<li><strong>Class:<\/strong> <strong>Highly selective, non-covalent (reversible) BTK inhibitor<\/strong><\/li>\n\n\n\n<li><strong>Key Innovation:<\/strong> Maintains efficacy in patients who have developed resistance to covalent BTK inhibitors<\/li>\n\n\n\n<li><strong>Commercial Partnership:<\/strong> <strong>Innovent Biologics<\/strong> holds commercialization rights in mainland China<\/li>\n\n\n\n<li><strong>Therapeutic Advantage:<\/strong> Reversible binding allows for sustained target inhibition without permanent enzyme modification<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-market-positioning\" class=\"wp-block-heading\">Strategic Market Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Competitive Landscape<\/th><th>Jaypirca Advantage<\/th><\/tr><\/thead><tbody><tr><td><strong>Covalent BTK inhibitors<\/strong> (ibrutinib, acalabrutinib, zanubrutinib)<\/td><td>Effective in covalent BTKi-resistant patients<\/td><\/tr><tr><td><strong>Treatment sequencing limitations<\/strong><\/td><td>Approved for <strong>all lines of therapy<\/strong> without prior treatment restrictions<\/td><\/tr><tr><td><strong>Resistance development<\/strong><\/td><td>Non-covalent mechanism overcomes common resistance mutations<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The CHMP recommendation represents a significant expansion beyond current BTK inhibitor paradigms, which typically require specific prior treatment sequences or exclude patients with BTK inhibitor resistance.<\/p>\n\n\n\n<h2 id=\"h-commercial-implications\" class=\"wp-block-heading\">Commercial Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Expansion:<\/strong> Unrestricted line-of-therapy approval captures broader patient population across treatment continuum<\/li>\n\n\n\n<li><strong>Competitive Differentiation:<\/strong> Only BTK inhibitor approved regardless of prior BTK inhibitor exposure<\/li>\n\n\n\n<li><strong>Revenue Trajectory:<\/strong> Builds on established China approvals with European market entry potential<\/li>\n\n\n\n<li><strong>Partnership Value:<\/strong> Strengthens Innovent Biologics&#8217; position in China&#8217;s hematologic malignancy market<\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> European Commission final decision expected within 67 days of CHMP positive opinion<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">This all-line approval positions Jaypirca as a potential new standard of care in CLL treatment, offering clinicians unprecedented flexibility in treatment sequencing and addressing a critical unmet need in BTK inhibitor-resistant disease.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to regulatory decisions, competitive dynamics, and market adoption patterns.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines&#8230;<\/p>\n","protected":false},"author":1,"featured_media":69040,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[16,199,911,15,33],"class_list":["post-69038","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-eli-lilly","tag-nyse-lly","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Eli Lilly&#039;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=69038\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eli Lilly&#039;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use\" \/>\n<meta property=\"og:description\" content=\"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency&#039;s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=69038\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-29T13:23:36+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-29T13:23:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Eli Lilly&#8217;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use\",\"datePublished\":\"2026-06-29T13:23:36+00:00\",\"dateModified\":\"2026-06-29T13:23:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038\"},\"wordCount\":363,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2902.webp\",\"keywords\":[\"Cancer\",\"Eli Lilly\",\"NYSE: LLY\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69038#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=69038\",\"name\":\"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2902.webp\",\"datePublished\":\"2026-06-29T13:23:36+00:00\",\"dateModified\":\"2026-06-29T13:23:37+00:00\",\"description\":\"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=69038\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2902.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/06\\\/2902.webp\",\"width\":1080,\"height\":608,\"caption\":\"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=69038#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eli Lilly&#8217;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use - Insight, China&#039;s Pharmaceutical Industry","description":"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=69038","og_locale":"en_US","og_type":"article","og_title":"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use","og_description":"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.","og_url":"https:\/\/flcube.com\/?p=69038","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-29T13:23:36+00:00","article_modified_time":"2026-06-29T13:23:37+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=69038#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=69038"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Eli Lilly&#8217;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use","datePublished":"2026-06-29T13:23:36+00:00","dateModified":"2026-06-29T13:23:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=69038"},"wordCount":363,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=69038#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","keywords":["Cancer","Eli Lilly","NYSE: LLY","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=69038#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=69038","url":"https:\/\/flcube.com\/?p=69038","name":"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=69038#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=69038#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","datePublished":"2026-06-29T13:23:36+00:00","dateModified":"2026-06-29T13:23:37+00:00","description":"Eli Lilly and Company (NYSE: LLY) announced on June 26, 2026, that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Jaypirca (pirtobrutinib) for the treatment of adult patients with chronic lymphocytic leukemia (CLL) across all lines of therapy and regardless of prior BTK inhibitor treatment history.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=69038#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=69038"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=69038#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","width":1080,"height":608,"caption":"Eli Lilly's Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=69038#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Eli Lilly&#8217;s Jaypirca Wins CHMP Recommendation for All-Line CLL Treatment Regardless of Prior BTK Inhibitor Use"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/06\/2902.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69038","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=69038"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69038\/revisions"}],"predecessor-version":[{"id":69041,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/69038\/revisions\/69041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/69040"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=69038"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=69038"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=69038"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}